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Obesity and its associated metabolic diseases represent some of the most rapidly expanding health issues
worldwide, and, thus, the development of a novel chemical compound to suppress adipogenesis is
strongly expected. We herein investigated the effects of water-soluble fullerene derivatives: a bis-
malonic acid derivative and three types of proline-type fullerene derivatives, on adipogenesis using NIH-
3T3 cells overexpressing PPARγ. One of the proline-type fullerene derivatives (P3) harboring three car-
boxy groups signiﬁcantly inhibited lipid accumulation and the expression of adipocyte-speciﬁc genes,
such as aP2, induced by the PPARγ agonist rosiglitazone. On the other hand, the bis-malonic acid deri-
vative (M) and the 2 other proline-type fullerene derivatives (P1, P2), which have two carboxy groups,
had no effect on PPARγ-mediated lipid accumulation or the expression of aP2. P3 fullerene also inhibited
lipid accumulation induced by the combined stimulation with 3-isobutyl-1-methylxanthine (IBMX),
dexamethasone, and insulin in 3T3-L1 preadipocytes. During the differentiation of 3T3-L1 cells into
adipocytes, P3 fullerene did not affect the expression of C/EBPδ, C/EBPβ, or PPARγ, but markedly in-
hibited that of aP2 mRNA. These results suggest that P3 fullerene exhibits anti-obesity activity by pre-
venting the activation of PPARγ.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Obesity is a major public health issue worldwide because it is a
signiﬁcant risk factor for a number of serious metabolic diseases
such as heart disease, type 2 diabetes, atherosclerosis, and cancer
[1,2]. An excess energy intake and lack of energy expenditure lead
to adipogenesis and the accumulation of excessive amounts of li-
pids in adipocytes, which elevates triglyceride contents in plasma
and tissues such as the liver and muscle, and ultimately results in
pathological dysfunctions in these tissues [3,4]. Therefore, com-
pounds that prevent the differentiation of adipocytes have po-
tential as anti-obesity drugs.B.V. This is an open access article u
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oshi-Tago).The mechanisms underlying adipogenesis have been elucidated
using murine 3T3-L1 preadipocytes. When treated with differ-
entiation inducers termed MDI, which consist of 3-isobutyl-1-
methylxanthine (IBMX), dexamethasone, and insulin, 3T3-L1 pre-
adipocytes differentiate into adipocytes, and this is regulated by
the sequential expression of transcription factors such as CCAAT/
enhancer-binding proteins (C/EBPs) and peroxisome proliferator-
activated receptor γ (PPAR γ). The expression of C/EBPδ and C/
EBPβ is induced in early adipocyte differentiation. C/EBPδ and C/
EBPβ then cooperatively transactivate the expression of PPARγ, a
master transcription factor for terminal adipocyte differentiation
[5–7]. PPARγ induces the expression of adipogenic genes, includ-
ing adipocyte Protein 2 (aP2), Glut4, and obesity genes, leading to
the adipocyte phenotype [8–10].
Fullerene (C60) is a spherical carbon molecule with a diameter
of 0.7 nm, and is a new type of organic compound with a cage-like
structure [11,12]. Since fullerene is poorly soluble in aqueous
media, many water-soluble fullerene derivatives have been de-
veloped using modiﬁcations with hydrophilic groups in the C60
core. Several water-soluble fullerene derivatives have been re-
ported to possess various biological and pharmacological proper-
ties [13,14]. A pyrrolidinium fullerene derivative has been shownnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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species (ROS), indicating their potential as anti-cancer drugs
[15,16]. On the other hand, previous studies showed that a bis-
malonic acid fullerene derivative exhibited potent anti-oxidant
activity [17,18]. We recently demonstrated that a bis-malonic acid
fullerene exhibited anti-inﬂammatory activity by inhibiting the
activation of nuclear factor kappa B (NF-κB), which is a key tran-
scription factor in mast cells (unpublished data). Furthermore, a
proline-modiﬁed fullerene derivative was shown to exhibit anti-
viral activity by inhibiting human immunodeﬁciency virus (HIV)-
reverse transcriptase and Hepatitis C virus RNA polymerase [19].
In the present study, we investigated the effects of fullerene
derivatives on adipogenesis in order to clarify their anti-obesity
activities. The results obtained demonstrated that a proline-type
fullerene derivative, but not a bis-malonic acid fullerene derivative
signiﬁcantly inhibited lipid accumulation induced by the PPARγ
agonist rosiglitazone in NIH-3T3 cells expressing PPARγ. The
proline-type fullerene derivative also inhibited the differentiation
of 3T3-L1 cells into adipocytes by preventing the activation of
PPARγ. These results conﬁrmed the potential of proline-type full-
erene derivatives as novel anti-obesity drugs.2. Materials and methods
2.1. Reagents and antibodies
A bis-malonic acid fullerene derivative and proline-type full-
erene derivatives were synthesized as described previously
[18,19]. Insulin, 3-isobutyl-1-methylxanthine (IBMX), and dex-
amethasone were purchased from CAYMAN CHEMICAL COMPANY
(East Ellsworth Road Ann Arbor, MI, USA). Rosiglitazone and di-
methyl sulfoxide (DMSO) were purchased from SIGMA ALDRICH
(St. Louis, MO, USA) and Nacalai Tesque (Tokyo, Japan), respec-
tively. Anti-C/EBPδ, anti-C/EBPβ, anti-PPARγ, and anti-β-actin an-
tibodies were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA).
2.2. Retroviral infection and cell cultures
The murine ﬁbroblasts, NIH-3T3 cells were infected with an
empty virus and retrovirus coding PPARγ-Flag as described
previously [20]. Infected NIH-3T3 cells and murine 3T3-L1
preadipocytes were cultured at 37 °C with 5% CO2-enriched air
in DMEM (Nacalai Tesque) supplemented with 10% fetal bovine
serum (FBS) (BioWest), 100 units/mL penicillin, and 100 μg/mL
streptomycin (Nacalai Tesque). In order to induce differentia-
tion, conﬂuent 3T3-L1 cells were treated with 5 mM IBMX,
1 μM dexamethasone, and 10 μg/mL insulin (MDI). After 3 days,
the medium was changed to DMEM supplemented with 10%
FBS, 100 units/mL penicillin, 100 μg/mL streptomycin, and 10 μg
mL insulin and cultured for another 2 days as previously de-
scribed [21].
2.3. Oil-red O staining and quantiﬁcation
3T3-L1 preadipocytes (3104/well) were seeded on 96-well
plates and adipocyte differentiation was induced for 6 days. the
infected NIH-3T3 cells were seeded on 96-well plates and treated
with rosiglitazone (1 μM) for 5 days. cells were washed with
phosphate-buffered saline (PBS) and ﬁxed with 10% formalin for
30 min, then washed with 60% isopropanol. after air drying, 0.3%
oil-red O solution was added to each well, and incubated at room
temperature for 30 min. after the solution was removed, cells werewashed with distilled water and air dried. Oil-red O in triglyceride
droplets was extracted with 100% isopropanol and determined at
OD490 for quantiﬁcation as previously described [22].
2.4. RNA isolation and reverse transcription-polymerase chain re-
action (RT-PCR)
RNA was prepared using Trizol (Life Technologies, Waltham,
MA, USA). The reverse transcription reaction was performed
using an oligo (dT)20 primer and 2 μg of total RNA for ﬁrst-strand
cDNA synthesis, as described previously [21]. Quantitative real-
time PCR was performed using an iCycler detection system (Bio-
Rad, Berkeley, CA, USA). PCR was performed in 25 μL with SYBR
Green Supermix, SsoFast EvaGreen (Bio-Rad). The PCR primer
sequences used were as follows: C/EBPβ, 5′-ACAGCGACGAGTA-
CAAGATCC-3′ (upstream) and 5′- GACAGTTGCTCCACCTTCTTCT-3′
(downstream); C/EBPδ, 5′-ATCGACTTCAGCGCCTACAT-3′ (up-
stream) and 5′-GCTTTGTGGTTGCTGTTGAA-3′ (downstream);
PPARγ, 5′-AACTCTGGGAGATTCTCCTGTTGA-3′ (upstream) and 5′-
TGGTAATTTCTTGTGAAGTGCTCATA-3′ (downstream); aP2, 5′-
CATCAGCGTAAATGGGGATT-3′ (upstream) and 5′-TCGACTTTC-
CATCCCACTTC-3′ (downstream); β-actin, 5′-TGTCCACCTTCCAG-
CAGATGT-3′ (upstream) and 5′-AGCTCAGTAACAGTCCGCCTAGA-3′
(downstream).
2.5. Immunoblotting
Cell lysates were prepared with Nonidet P-40 lysis buffer
(50 mM Tris–HCl, pH 7.4, 10% glycerol, 50 mM NaCl, 0.5% sodium
deoxycholate, 1% Nonidet P-40, 20 mM NaF, and 0.2 mM Na3VO4)
supplemented with protease inhibitors. Proteins were denatured
by adding Laemmli's sample buffer, and then resolved on 10% SDS-
PAGE and transferred to PVDF membranes. Immunoblotting was
performed as previously described [20].
2.6. Statistics
The signiﬁcance of differences in Oil-red O staining and mRNA
expression levels was determined using the Student's t-test with a
conﬁdence level of 95% (Po0.05).3. Results
3.1. Rosiglitazone induced the accumulation of lipid droplets and
expression of aP2 in NIH-3T3 cells expressing PPARγ
The murine ﬁbroblasts, NIH-3T3 cells were infected with a
retrovirus harboring the cDNA of PPARγ-Flag, which is a master
regulator for adipocyte differentiation (Fig. 1A). We determined
whether these cells differentiated into adipocyte-like cells using
the PPARγ agonist, rosiglitazone. NIH-3T3 cells expressing PPARγ
were treated with rosiglitazone for 5 days, adipogenesis was as-
sessed by Oil-Red O staining of lipid droplets, and lipid contents
were quantiﬁed by measuring absorbance at 490 nm. The en-
forced expression of PPARγ induced lipid accumulation slightly
more in NIH-3T3 cells than in cells infected with the empty virus
(pBabe-Puro). Rosiglitazone markedly induced lipid accumula-
tion in NIH-3T3 cells expressing PPARγ (Fig. 1B and C). Further-
more, whereas the expression of PPARγ slightly induced the ex-
pression of aP2 mRNA, an adipocyte-speciﬁc gene, in NIH-3T3
cells, rosiglitazone markedly induced its expression in NIH-3T3
cells expressing PPARγ, but not in NIH-3T3 cells infected with the
control virus (Fig. 1D).
Fig. 1. Rosiglitazone induces the accumulation of lipid droplets and expression of aP2 in NIH-3T3 cells expressing PPARγ. (A) NIH-3T3 cells were infected with an empty virus
(pBabe Puro) and retrovirus expressing PPARγ-Flag. Whole cell lysates were immunoblotted with an anti-PPARγ, anti-Flag, or anti-β-actin antibody. (B) Infected NIH-3T3 cells
were treated with rosiglitazone (RGZ) (1 μM) for 5 days. Cells were stained with Oil-Red O. (C) The intensity of Oil-Red O staining was quantiﬁed by measuring absorbance at
490 nm (A490). Values are given as the mean7standard deviation (SD) of three independent experiments. Data were analyzed using the Student's t-test. * and *** indicate
po0.05 and po0.001, respectively. (D) Infected NIH-3T3 cells were treated with RGZ (1 μΜ) for the indicated periods. Total RNA was prepared and the mRNA expression of
aP2 was analyzed by quantitative real-time PCR. β-actin mRNA was analyzed as an internal control. Values are the mean7S.D. of three independent experiments. * and ***
indicate po0.05 and po0.001, respectively.
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lipid droplets and expression of aP2 in NIH-3T3 cells expressing PPARγ
In order to investigate the effects of fullerene derivatives on
adipocyte differentiation, we investigated whether fullerene de-
rivatives such as the bis-malonic acid fullerene derivative (M) and
three kinds of proline-type fullerene derivatives (P1, P2, and P3)
affected adipogenesis-like lipid accumulation in NIH-3T3 cells
expressing PPARγ (Fig. 2A).
The bis-malonic acid fullerene derivative (M) had no effect on
rosiglitazone-induced lipid accumulation. Two of the proline-type
fullerene derivatives, which have two carboxy groups (P1, P2), had
no effect on rosiglitazone-induced lipid accumulation, whereas the
proline-type fullerene derivative with three carboxy groups (P3)
signiﬁcantly inhibited it (Fig. 2B and C). P3 fullerene signiﬁcantly
inhibited the rosiglitazone-induced expression of aP2 mRNA in a
dose-dependent manner. On the other hand, the other fullerenes,
M, P1, and P2, failed to inhibit the expression of aP2 induced by
rosiglitazone (Fig. 2D).
3.3. A proline-type fullerene derivative inhibited the MDI-induced
accumulation of lipid droplets and expression of aP2 in 3T3-L1 cells
We next examined whether P3 fullerene inhibited the differ-
entiation of 3T3-L1 preadipocytes into adipocytes. The effects of P3fullerene on the adipogenesis of 3T3-L1 cells were assessed by
staining lipid droplets with Oil-Red O, and lipid contents were
quantiﬁed by measuring absorbance at 490 nm. P3 fullerene sig-
niﬁcantly inhibited MDI-induced lipid accumulation in 3T3-L1
cells (Fig. 3A and B). It also markedly inhibited MDI-induced aP2
expression (Fig. 3C), indicating that P3 fullerene prevents adipo-
genesis by inhibiting the activation of PPARγ.
3.4. A proline-type fullerene derivative had no effect on the expres-
sion of C/EBPδ, C/EBPβ, or PPARγ during the differentiation of 3T3-L1
cells into adipocytes
We next investigated the effects of P3 fullerene on the ex-
pression of a series of transcription factors required for adipo-
genesis such as C/EBPs and PPARγ during adipogenesis by per-
forming quantitative RT-PCR and immunoblotting. The expression
of C/EBPδ and C/EBPβ mRNAs was induced 1 day after the treat-
ment with MDI, and the expression of PPARγ mRNA was induced
thereafter. P3 fullerene had no effect on the MDI-induced ex-
pression of C/EBPδ mRNA, C/EBPβ mRNA, or PPARγ mRNA
(Fig. 4A). Consistent with mRNA expression levels, P3 fullerene
had no effect on the MDI-induced protein expression of C/EBPδ, C/
EBPβ, or PPARγ (Fig. 4B). Since PPARγ mRNA is known to be in-
duced by C/EBPδ and C/EBPβ [7–9], P3 fullerene may have failed to
Fig. 2. A proline-type fullerene derivative inhibits the rosiglitazone-induced accumulation of lipid droplets and expression of aP2 in NIH-3T3 cells expressing PPARγ.
(A) Structures of the bis-malonic acid fullerene derivative (M) and proline-type fullerene derivatives (P1, P2, and P3). (B) NIH-3T3 cells expressing PPARγ were treated with
rosiglitazone (RGZ) (1 μM) in the presence of fullerene derivatives (1, 3, 10, and 30 μM) for 5 days. Cells were stained with Oil-Red O. (C) Oil-Red O staining was quantitatively
evaluated by measuring A490. Values are the mean7S.D. of three independent experiments. Data were analyzed using the Student's t-test. * indicates po0.05. (D) NIH-3T3
cells expressing PPARγ were treated with RGZ (1 μM) in the presence of fullerene derivatives for 4 days. Total RNA was prepared and the mRNA expression of aP2 was
analyzed by quantitative real-time PCR. β-actin mRNAwas analyzed as an internal control. Values are the mean7S.D. of three independent experiments. Data were analyzed
using the Student's t-test. * and ** indicate po0.05 and po0.01, respectively.
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their activities.4. Discussion
Fullerenes may be functionally derivatized by numerous
types of chemical modiﬁcations, and have been investigated as
novel tools to diagnose, monitor, and treat various diseases [11–
14]. A previous study showed that proline-type fullerene deri-
vatives exhibited anti-viral activity against HIV and Hepatitis C
[19]. Proline-type fullerene derivatives were recently found to
inhibit the endonuclease activity of PA, a subunit of inﬂuenza A
virus, and this inhibitory effect induced resistance to Inﬂuenza A
viral infection [22]. These ﬁndings indicate the potential of
proline-type fullerene derivatives as novel anti-viral drugs in the
future. In the present study, we showed that one of the proline-
type fullerene derivatives examined signiﬁcantly inhibited the
adipogenesis of 3T3-L1 cells (Fig. 3). This is the ﬁrst study to
suggest the potential of proline-type fullerene derivatives in the
treatment or prevention of obesity. The proline-type fullerene
derivative, P3 fullerene speciﬁcally inhibited the activation of
PPARγ, which is the master transcriptional regulator of adipo-
cyte differentiation and controls the expression of a series of
genes involved in lipid metabolism (Figs. 2 and 3). A comparison
of the structures of the three kinds of proline-type fullerene
derivatives tested in this study revealed that three carb-
oxy groups were necessary for fullerene derivatives to exhibitinhibitory activity against the activation of PPARγ and accumu-
lation of lipid droplets (Fig. 2).
Xiao et al. previously reported that a highly hydroxylated full-
erene derivative inhibited H2O2-stimulated lipid accumulation in
3T3-L1 cells [23]. These ﬁndings also support the application of a
fullerene derivative as an anti-obesity drug; however, the in-
hibitory mechanism underlying adipogenesis by highly hydro-
xylated fullerene derivatives has not yet been elucidated in detail,
and appears to differ from that of proline-type fullerene deriva-
tives. In obesity, ROS are generated from over-expanded adipose
tissue [24,25]. Highly hydroxylated fullerene derivatives are highly
reactive with radical species and inhibit lipid uptake-induced ROS
generation in OP9 preadipocytes, a reduction that appears to
correlate with decreases in the expression of PPARγ [23]. However,
it currently remains unclear whether oxidative stress is involved in
adipogenesis or the induction of PPARγ expression. On the other
hand, the expression level of PPARγ was not changed in 3T3-L1
cells treated with P3 fullerene (Fig. 4). In addition, although a bis-
malonic acid fullerene derivative exhibited potent anti-oxidant
activity [17], it failed to inhibit adipogenesis or the activation of
PPARγ (Fig. 2). Therefore, the inhibitory effects of P3 fullerene on
adipogenesis are unrelated to its reactivity with ROS.
Adipogenesis is a unique biological event, which is processed
by the sequential activation of three transcription factors, C/EBPβ,
C/EBPα, and PPARγ through the induction of their expressions [5–
7]. Although the endogenous ligand for PPARγ is not identiﬁed, P3
fullerene suppresses the rosiglitazone-induced lipid accumulation
and mRNA expression of aP2 (Fig. 2), suggesting that P3 fullerene
Fig. 3. A proline-type fullerene derivative inhibits the MDI-induced accumulation of lipid droplets and expression of aP2 in 3T3-L1 cells. 3T3-L1 cells were treated with a
proline-type fullerene derivative (P3) (10 μM) and MDI. (A) Cells were stained by Oil-Red O on day 6 after the treatment with MDI. (B) Oil-Red O staining was quantiﬁed by
measuring A490. Values are the mean7S.D. of three independent experiments. Data were analyzed using the Student's t-test. * and *** indicate po0.05 and po0.001,
respectively. (C) Total RNA was prepared on day 6 after the treatment with MDI. The expression of aP2 mRNA was analyzed by quantitative real-time PCR. β-actin mRNA was
analyzed as an internal control. Values are the mean7S.D. of three independent experiments. Data were analyzed using the Student's t-test. * and ** indicate po0.05 and
po0.01, respectively.
Fig. 4. A proline-type fullerene derivative has no effect on the expression of C/EBPs or PPARγ in 3T3-L1 cells. (A, B) 3T3-L1 cells were treated with a proline-type fullerene
derivative (P3) (10 μM) and MDI for 3 days. (A) Total RNA was prepared and the expression of C/EBPδ, C/EBPβ, and PPARγmRNAs was analyzed by quantitative real-time PCR.
β-actin mRNAwas analyzed as an internal control. Values are the mean7S.D. of three independent experiments. (B) Whole cell lysates were immunoblotted with an anti- C/
EBPδ, anti-C/EBPβ, anti-PPARγ, or anti-β-actin antibody.
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cludes the binding elements for PPARγ, therefore aP2 is under-
stood as a direct target gene of PPARγ [8,9]. Transcription induced
by PPARγ is also reported to be accelerated by histone modiﬁca-
tion, such as acetylation induced by P300/CBP and PGC-1α [26]. In
the current study, we do not have enough explanation how P3
fullerene inhibits PPARγ-induced transcription. P3 fullerene could
suppress the PPARγ-caused transcription mediated three possible
mechanisms such as (1) P3 fullerene may block the ligand binding
to PPARγ, (2) P3 fullerene may inhibit the DNA binding activity of
PPARγ, and (3) P3 fullerene may suppress the transcriptional ac-
tivation by PPARγ. To clarify the molecular mechanism, by which
P3 fullerene inhibits PPARγ-induced transcription, the detailed
analysis such as in vitro ligand binding assay and DNA binding
assay would be suitable. In addition, the analysis of protein com-
plexes including PPARγ would provide the molecular basis how
PPARγ is activated, and these knowledge would help us to un-
derstand how P3 fullerene inhibits the adipogenesis.
In the future study, it is important to determine whether P3
fullerene exhibits anti-obesity activity in vivo. Although PPARγwas
originally discovered as a pivotal regulator of adipocyte differ-
entiation, it has been reported to have various functions. The ex-
pression of PPARγ has been detected in various cancer cells in-
cluding breast, colon, and non-small cell lung cancers, where
PPARγ regulates cell proliferation, differentiation, and apoptosis
[27–31]. Previous studies reported that ligand-induced PPARγ ac-
tivation inhibited the invasion and metastasis of breast cancer cells
[32,33]. Furthermore, the in vivo administration of PPARγ ligands
prevented the development of leptin-induced MCF-7 tumor xe-
nografts in nude mice [34]. Previous studies also reported that
heterozygous mice in which one allele of PPARγ was deleted
(PPARγ þ/) were more susceptible to experimentally induced
arthritis and allergic encephalomyelitis, suggesting that PPARγ has
anti-inﬂammatory functions [35,36]. These ﬁndings suggest that
the administration of proline-type fullerenes in vivo will increases
the risk of exacerbating cancer and excess inﬂammation responses
through the inhibition of PPARγ. Therefore, the development of
tissue-speciﬁc PPARγ inhibitors is needed for more effective and
safer therapies against obesity.Acknowledgments
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